Impacts of CD36 Variants on Plasma Lipid Levels and the Risk of Early‐Onset Coronary Artery Disease: A Systematic Review and Meta‐Analysis
Cardiovascular Therapeutics · 2025
DOI: 10.1155/cdr/8098173 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Cardiovascular Therapeutics, 2025. Verfasst von Zhi Luo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Suining Central Hospital, Suining, Sichuan, China. Hauptthemen laut MEDLINE: CD36 Antigens, Coronary Artery Disease, Dyslipidemias, Lipids. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Recent studies have indicated that cluster of differentiation 36 (CD36) is closely linked to dyslipidemia and early‐onset coronary artery disease (EOCAD). This study is aimed at investigating the impacts of CD36 gene variants on lipid profiles and EOCAD risk.
Methods
PubMed, Cochrane Library, Central, CINAHL, and ClinicalTrials.gov were searched until June 15, 2024.
Results
In total, 25 studies (11,494 individuals) were included for the analysis. The A allele carriers of the rs1761667 variant had higher high‐density lipoprotein cholesterol (HDL‐C) levels and higher EOCAD risk than noncarriers. In contrast, the G allele carriers of the rs1049673 and rs3211956 variants had lower low‐density lipoprotein cholesterol (LDL‐C) levels and lower EOCAD risk than noncarriers. Subgroup analysis indicated that the antiatherosclerotic impact and reduced EOCAD risk were primarily observed in Chinese with rs1049673 and rs3211956.
Conclusions
The rs1761667, rs1049673, and rs3211956 variants of the CD36 gene have significant impacts on lipid levels and may serve as genetic markers for the risk of EOCAD primarily in Chinese. The impacts of CD36 variants on EOCAD risk are mediated, at least partly, by dyslipidemia. Genetic screening of CD36 gene variants may be helpful for early intervention or prevention of EOCAD in individuals with high risk factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Suining Central Hospital, Suining, Sichuan, China.
- Department of Orthopedics, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
ORCID-Profile: Zhi Luo, Lingwei Lv
Zitieren
APA
Luo, Z., & Lv, L. (2025). Impacts of CD36 Variants on Plasma Lipid Levels and the Risk of Early‐Onset Coronary Artery Disease: A Systematic Review and Meta‐Analysis. Cardiovascular Therapeutics. https://doi.org/10.1155/cdr/8098173
Vancouver
Luo Z, Lv L. Impacts of CD36 Variants on Plasma Lipid Levels and the Risk of Early‐Onset Coronary Artery Disease: A Systematic Review and Meta‐Analysis. Cardiovascular Therapeutics. 2025. doi:10.1155/cdr/8098173
BibTeX
@article{Luo2025,
author = {Luo, Zhi and Lv, Lingwei},
title = {Impacts of CD36 Variants on Plasma Lipid Levels and the Risk of Early‐Onset Coronary Artery Disease: A Systematic Review and Meta‐Analysis},
journal = {Cardiovascular Therapeutics},
year = {2025},
doi = {10.1155/cdr/8098173}
}
EUVIMED